NYSE$HAE

Haemonetics Corp. · Q4 2020 earnings

Q4 2020 earnings · · Investor relations

Briefing

Haemonetics' Q4 2020 results were reported, revealing a decrease in revenue but an increase in gross margin and operating income compared to the same period last year.

Haemonetics reported a decrease in revenue for Q4 2020, with a 4.3% drop to $238.5 million. However, the company saw improvements in gross margin, which rose by 300 basis points to 47.6%, and operating income, which increased by 9.0% to $26.0 million. Net income decreased by 15.4% to $17.6 million, with earnings per diluted share down 15.0% to $0.34.

  • Q4 2020 revenue decreased by 4.3% to $238.5 million.
  • Gross margin increased by 300 basis points to 47.6%.
  • Operating income increased by 9.0% to $26.0 million.
  • Net income decreased by 15.4% to $17.6 million.

Headline financials

Total Revenue

$238M

Previous: $249M-4.3%
EPS (adj)

$0.69

Previous: $0.61+13.1%
Adjusted gross margin

50.3%

No prior period
Adjusted operating margin

19.8%

No prior period
Capital Expenditures

$10.6M

Previous: $13.7M-22.4%
Free Cash Flow

$35.8M

Previous: $6.92M+416.6%
Net Income

$17.6M

Previous: $20.8M-15.4%
Operating Income

$26M

Previous: $23.9M+9.0%
Gross Profit

$114M

Previous: $111M+2.1%
Cash & Equivalents

$137M

Previous: $169M-18.9%
Total Assets

$1.27B

Previous: $1.27B-0.6%
Stock-Based Comp

$5.4M

Previous: $4.45M+21.5%

Revenue & EPS history

Haemonetics · Revenue · Quarterly

$238M

Q4 2020-4.3%vs Q4 2019
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

Haemonetics · $234M total across 3 segments · Q4 2020

  • Plasma
    $112M+3.8%
  • Blood Center
    $76.6M-10.8%
  • Hospital
    $45.8M-8.6%

Forward guidance

Given the uncertainty around the full impact and duration of the COVID-19 pandemic, and the nature and timing of the associated economic recovery, Haemonetics is not issuing annual guidance at this time. The Company is currently assessing potential scenarios for the macroeconomic impact of COVID-19 and the related effect on healthcare beyond the current quarter, informed by milestones and market indicators that unfold over the coming weeks. As a result the Company intends to issue guidance later in its fiscal year.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2020

Historical avgQ4 2020

+1.4%

Avg return

Earnings day

+4.1%

Avg return

5 days after

+6.5%

Avg return

30 days after

56%

38 / 68 earnings

Positive

+31.8%

Q2 2026

Best reaction

-15.0%

Q4 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+3.3%+2.5%+35.5%
Q3 2026-1.4%-9.8%-2.8%
Q2 2026+31.8%+41.4%+65.5%
Q4 2025+5.9%+7.6%+9.7%
Q3 2025-11.6%-13.6%-3.6%
Q2 2025+11.8%+19.5%+3.9%
Q1 2025-10.1%-13.4%-14.6%
Q4 2024+2.8%+4.4%-8.2%
Q3 2024-3.8%-7.0%+3.2%
Q2 2024+2.4%+2.5%-2.5%
Q1 2024+2.0%+3.0%-0.8%
Q4 2023+7.6%+7.4%+6.1%
Q3 2023-5.4%-8.2%-12.2%
Q2 2023+4.1%-1.7%+3.5%
Q1 2023+8.1%+12.3%+13.7%
Q4 2022+3.9%+14.1%+31.5%
Q3 2022+21.2%+24.5%+18.9%
Q2 2022-13.5%-15.7%-24.8%
Q1 2022+8.4%+1.8%+16.8%
Q4 2021-6.4%-5.4%+0.4%
Q3 2021+12.8%+21.1%+4.0%
Q2 2021-3.7%+5.6%+13.2%
Q1 2021-12.7%-8.5%+3.3%
Q4 2020-8.8%-3.4%-11.1%
Q3 2020+7.2%+7.7%-7.3%
Q2 2020+0.3%+0.5%-0.1%
Q1 2020+10.5%+13.5%+10.8%
Q4 2019+2.8%+3.4%+10.0%
Q3 2019-12.2%-14.3%-13.0%
Q2 2019+9.1%+5.8%-0.2%
Q1 2019+4.8%+2.7%+14.4%
Q4 2018+5.8%+11.2%+18.9%
Q3 2018+14.8%+13.1%+20.5%
Q2 2018+15.8%+16.4%+20.8%
Q1 2018+4.2%+3.2%+3.9%
Q4 2017-1.9%-4.4%-4.0%
Q3 2017-10.1%-9.0%-7.3%
Q2 2017+10.5%+13.8%+16.5%
Q1 2017+13.8%+16.8%+22.6%
Q4 2016-15.0%
Q3 2016+5.9%
Q2 2016-3.9%
Q1 2016+1.5%
Q4 2015-3.9%
Q3 2015+7.0%
Q2 2015-5.9%
Q1 2015-1.4%
Q4 2014-8.0%
Q3 2014-2.6%
Q2 2014+1.5%
Q1 2014+0.7%
Q4 2013-1.4%
Q3 2013-5.6%
Q2 2013+4.3%
Q1 2013-0.1%
Q4 2012+4.2%
Q3 2012-1.0%
Q2 2012+0.4%
Q1 2012+3.1%
Q4 2011+1.3%
Q4 2009+1.3%
Q3 2010-1.3%
Q3 2011-1.3%
Q2 2011+1.7%
Q1 2010-2.5%
Q2 2010-2.5%
Q1 2011-2.5%
Q4 2010-2.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro